Octave Specialty Group (OSG) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Insurance Distribution revenues surged 92% year-over-year, driven by 42% organic growth and the ArmadaCare acquisition, with total P&C premium production up 66% to $531 million.
Adjusted EBITDA for insurance distribution reached $25.3 million (32% margin), nearly quadrupling year-over-year, and consolidated adjusted EBITDA to shareholders was $20.1 million, up from a loss of $1.3 million.
Net loss to shareholders improved to $6.9–$7 million from $16–$16.1 million in Q1 2025, with insurance distribution posting $13.2 million net income.
Specialty P&C Insurance segment reported a net loss of $7.7 million, impacted by $7.9 million in litigation-related losses and expenses.
Strategic focus on organic growth, cost structure realignment, and leveraging data and AI for underwriting and operational efficiency.
Financial highlights
Insurance Distribution revenue grew to $78.5–$79 million, with premiums produced up 83% to $427 million and net income to shareholders at $13.2 million versus a $3.4 million loss last year.
Consolidated adjusted net income to shareholders was $16.6 million, up from a $6 million loss year-over-year.
Insurance Distribution Adjusted EBITDA increased to $25.3 million from $7.1 million, and adjusted net income rose to $22 million from $2.5 million.
Specialty P&C Insurance premiums written rose 19% to $104 million, with adjusted EBITDA to shareholders at $1.6 million.
Corporate expenses and Adjusted Corporate expenses decreased to $11.9 million and $7.2 million, respectively.
Outlook and guidance
Q1 performance was ahead of plan; 2026 guidance targets Insurance Distribution organic revenue growth of 20%+, Adjusted EBITDA of ~$40 million, Specialty Insurance GPW of ~$410 million, and consolidated Adjusted Net Income of ~$0.50 per share.
Expecting 1–2 new MGA launches in 2026, with a robust pipeline under evaluation.
No additional buy-ins of non-controlling interests planned for the remainder of the year.
The amendment to the credit agreement enhances financial flexibility for further acquisitions and capital management.
Latest events from Octave Specialty Group
- Shareholders to vote on board, compensation, auditor, and new incentive plan after major transformation.OSG
Proxy filing10 Apr 2026 - Board recommends approval of all annual meeting proposals, including director elections and compensation.OSG
Proxy filing10 Apr 2026 - Q4 2025 delivered strong premium and revenue growth, but net loss rose on acquisition costs.OSG
Q4 202524 Feb 2026 - AAC sale and Beat acquisition accelerate specialty P&C transformation and capital redeployment.OSG
Q2 20242 Feb 2026 - Legacy business sold to Oaktree and 60% of Beat acquired, accelerating specialty P&C focus.OSG
Investor Update31 Jan 2026 - Q3 net loss, 86% P&C premium growth, Beat acquisition, $50M buyback, legacy sale approved.OSG
Q3 202414 Jan 2026 - Revenue up 27% and P&C premium up 70%, but net loss widened on higher expenses.OSG
Q1 20257 Jan 2026 - Record premium growth and margin gains offset by $548M net loss from legacy business sale.OSG
Q4 202423 Dec 2025 - Vote on $420M sale of AAC to Oaktree, executive pay, and adjournment; board recommends approval.OSG
Proxy Filing2 Dec 2025